Palopegteriparatide
Also known as: AZP-3601, peg-PTH(1-34), TransCon PTH, Yorvipath
Source Palopegteriparatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Palopegteriparatide (brand name Yorvipath, also called TransCon PTH) is a prescription, subcutaneously administered, long‑acting analog of parathyroid hormone (PTH 1‑34) approved for treatment of adults with hypoparathyroidism. By replacing the missing hormone, it aims to normalize serum calcium, reduce dependence on oral calcium and active vitamin D, and improve related symptoms and quality of life.
Mechanism of Action
Palopegteriparatide is a prodrug that slowly releases the active PTH(1‑34) peptide, which binds the PTH1 receptor on renal tubular cells and osteoblasts/osteocytes. Activation of this G‑protein‑coupled receptor raises intracellular cAMP, increasing calcium reabsorption in the kidney, decreasing phosphate reabsorption, and stimulating bone remodeling. The once‑daily, sustained exposure mimics physiological PTH levels, favoring net bone formation while maintaining calcium homeostasis.
What the Research Shows
In the phase 3 PaTHway trial, 84 adults with chronic hypoparathyroidism were randomized 3:1 to daily TransCon PTH or placebo for 26 weeks. At week 26, 79 % of treated participants met a composite endpoint of normal calcium, independence from calcium/vitamin D, and stable dosing versus 5 % on placebo. Ninety‑three percent achieved full independence from conventional therapy, urinary calcium normalized, and health‑related quality‑of‑life scores improved. An open‑label extension through week 52 showed 81 % meeting a multicomponent efficacy endpoint, 95 % independence, bone mineral density Z‑scores returning toward age‑matched norms, and a 24‑hour urine calcium reduction from 376 mg to 195 mg. A post‑hoc renal analysis reported a mean eGFR increase of 9.3 mL/min/1.73 m², with greater gains in participants whose baseline eGFR was <60 mL/min/1.73 m². Treatment‑emergent adverse events were mostly mild or moderate, and no participants discontinued because of adverse events.
Reported Benefits
Trials demonstrate that palopegteriparatide can achieve normocalcemia without the need for high‑dose oral calcium or active vitamin D, markedly reducing pill burden. Patients report better physical functioning and overall well‑being. Bone mineral density trends toward normal, urinary calcium excretion falls, and renal function (eGFR) improves over one year. The safety profile in the studied cohort was favorable, with most adverse events being mild or moderate.
Limitations of the Evidence
Evidence is currently limited to a single phase 3 trial involving about 80 adults, with longer‑term data beyond 52 weeks still emerging. The open‑label extension lacks a placebo comparator, and the drug has not been studied in children, pregnant women, or patients with severe renal impairment. Direct comparisons with other PTH analogues such as teriparatide are unavailable, and rare or late‑emerging adverse effects remain unknown.
Safety Considerations
Most treatment‑emergent adverse events were mild or moderate and did not lead to discontinuation. Specific events were not detailed in the abstracts, but the overall safety profile aligns with other PTH therapies. Hypercalcemia was not reported as a common problem, yet regular monitoring of serum calcium, urinary calcium, and renal function is advised. Caution is warranted in patients with a history of hypercalcemia or severe kidney disease until more data are available.
How It Is Administered
Palopegteriparatide is given as a once‑daily subcutaneous injection. The formulation is a prodrug that releases PTH(1‑34) gradually, allowing titration to maintain serum calcium within the normal range. It is indicated for adult patients with hypoparathyroidism and is used in conjunction with calcium monitoring protocols.
Routes of Administration
Goals & Uses
- Normalization of serum calcium levelsEndocrine/MetabolicHigh
- Improvement of quality of life in hypoparathyroidismPatient Reported OutcomesModerate
- Reduction of calcium and vitamin D supplementation burdenEndocrine/MetabolicHigh
- Reduction of hypercalciuria and renal complicationsRenalModerate
- Treatment of chronic hypoparathyroidismEndocrine/MetabolicHigh
Contraindications
- Osteosarcoma risk conditions (Paget's disease, prior radiation therapy to skeleton)OncologicHigh
- Hypersensitivity to teriparatide or PEG componentsAllergy/ImmunologicHigh
- HypercalcemiaMetabolic DisorderHigh
- Pediatric patients with open epiphysesPediatricHigh
- Metabolic bone diseases other than hypoparathyroidismMusculoskeletalModerate
Adverse Effects
- HypercalcemiaMetabolicCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypercalciuriaMetabolicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- HypocalcemiaMetabolicCommon
Drug Interactions
- BisphosphonatesLow
- Active vitamin D analogs (calcitriol, alfacalcidol)Moderate
- Calcium supplementsModerate
- Thiazide diureticsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- History of nephrolithiasis or nephrocalcinosisRenalRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeAbsolute
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Chronic hypoparathyroidism in adultsEMA approved in 2023 under the brand name Yorvipath. Designated as an orphan medicinal product.
- United StatesApprovedApproved: Chronic hypoparathyroidism in adultsFDA approved in 2024 under the brand name Yorvipath. Received Orphan Drug Designation.
- United KingdomApprovedApproved: Chronic hypoparathyroidism in adultsApproved by MHRA following EMA authorization; available as Yorvipath.
Approved by the EMA in 2023 for adults with chronic hypoparathyroidism. FDA approved in 2024 under the brand name Yorvipath for the same indication. Developed by Ascendis Pharma using their TransCon technology platform.
Evidence & Sources
- Journal ArticleModerateClarke BL, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateKhan AA, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateBonnet AL, Aboishava L, Mannstadt M2025-01-01T00:00:00.000000Z
- Journal ArticleModerateKhan S, Khan AA2025-01-01T00:00:00.000000Z
- Journal ArticleModerateRejnmark L, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLowKhan AA, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
How does palopegteriparatide differ from conventional hypoparathyroidism therapy?
Conventional therapy relies on oral calcium salts and active vitamin D to raise serum calcium, but it does not replace the missing hormone and often requires multiple pills. Palopegteriparatide provides physiological PTH replacement, normalizing calcium levels while allowing patients to stop or greatly reduce calcium and vitamin D supplements.
What clinical outcomes have been shown in trials?
In the PaTHway trial, about 80 % of treated adults achieved normal calcium without calcium/vitamin D, 93 % became independent of conventional therapy, urinary calcium fell, bone density approached age‑matched norms, quality‑of‑life scores improved, and eGFR increased by roughly 9 mL/min after one year.
What are the most common side effects?
Adverse events reported were generally mild or moderate and included typical PTH‑related effects such as transient nausea, injection‑site reactions, or mild hypercalcemia, though serious events were rare and no participants stopped treatment because of side effects in the reported studies.
Who is eligible to receive palopegteriparatide?
The drug is approved for adult patients with chronic hypoparathyroidism who require calcium and active vitamin D supplementation. It is not currently indicated for children, pregnant or lactating women, or patients with severe renal impairment pending further data.
What is Palopegteriparatide?
Palopegteriparatide (brand name Yorvipath, also called TransCon PTH) is a prescription, subcutaneously administered, long‑acting analog of parathyroid hormone (PTH 1‑34) approved for treatment of adults with hypoparathyroidism. By replacing the missing hormone, it aims to normalize serum calcium, reduce dependence on oral calcium and active vitamin D, and improve related symptoms and quality of life.
What is Palopegteriparatide used for?
Palopegteriparatide is educationally associated with: Normalization of serum calcium levels, Improvement of quality of life in hypoparathyroidism, Reduction of calcium and vitamin D supplementation burden, Reduction of hypercalciuria and renal complications, Treatment of chronic hypoparathyroidism. Educational only — not medical advice.
How is Palopegteriparatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Palopegteriparatide?
Reported adverse effects include: Hypercalcemia, Injection site reactions, Headache, Hypercalciuria, Nausea, Hypocalcemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Palopegteriparatide?
Recorded contraindications: Osteosarcoma risk conditions (Paget's disease, prior radiation therapy to skeleton), Hypersensitivity to teriparatide or PEG components, Hypercalcemia, Pediatric patients with open epiphyses, Metabolic bone diseases other than hypoparathyroidism. Consult a qualified clinician before use.